Siponimod pharmacokinetics, safety and tolerability in combination with the CYP2C9/3A4 inducer, rifampin in healthy subjects

被引：0
|
作者：
Gardin, A. [1 ]
Gray, C. [2 ]
Neelakantham, S. [3 ]
Huth, F. [1 ]
Davidson, A. M. [4 ]
Dumitras, S. [1 ]
Legangneux, E. [1 ]
Shakeri-Nejad, K. [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[4] PPD, Austin, TX USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P796
引用
收藏
页码：409 / 409
页数：1
相关论文
共 50 条
  • [41] The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects
    Marta Hamilton
    Julie L. Wolf
    Daniel W. Drolet
    Scott H. Fettner
    Ashok K. Rakhit
    Karsten Witt
    Bert L. Lum
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 613 - 621
  • [42] CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs
    Schleiff, Mary Alexandra
    Crosby, Samantha
    Blue, Madison
    Schleiff, Benjamin Mark
    Boysen, Gunnar
    Miller, Grover Paul
    BIOCHEMICAL PHARMACOLOGY, 2021, 194
  • [43] Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population
    Zhang, M.
    Yang, Y.
    Zhao, G.
    Di, X.
    Xu, L.
    Jiang, N.
    Xu, J.
    Xu, X.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (01) : 831 - 837
  • [44] EFFECT OF CYP2C8 AND CYP2C9 AND GENDER ON PIOGLITAZONE PHARMACOKINETICS IN HEALTHY VOLUNTEERS
    Roman, M.
    Ochoa, M. D.
    Talegon, M.
    Rivas, A.
    Prieto, R.
    Cabaleiro, T.
    Abad, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 113 : 23 - 23
  • [45] Pharmacokinetics of glibenclamide and glimepiride in Finnish subjects with different CYP2C9 genotypes
    Timm, R
    Niemi, M
    Neuvonen, P
    Kroemer, HK
    Cascorbi, I
    Kivistö, KT
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : S98 - S98
  • [46] The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects
    Hamilton, Marta
    Wolf, Julie L.
    Drolet, Daniel W.
    Fettner, Scott H.
    Rakhit, Ashok K.
    Witt, Karsten
    Lum, Bert L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 613 - 621
  • [47] The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
    Meadowcroft, AM
    Williamson, KM
    Patterson, JH
    Hinderliter, AL
    Pieper, JA
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (04): : 418 - 424
  • [48] The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers
    Jetter, A
    Lazar, A
    Schömig, E
    Fuhr, U
    Kinzig-Schippers, M
    Sörgel, F
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) : 441 - 443
  • [49] Effects of CYP2C9*3 and CYP2C9*13 alleles on the pharmacokinetics of celecoxib and its carboxylic metabolite.
    Park, So-Young
    Lee, Hye-In
    Choi, Chang-Ik
    PHARMACOTHERAPY, 2012, 32 (10): : E235 - E235
  • [50] Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects
    Shakeri-Nejad, Kasra
    Gardin, Anne
    Gray, Cathy
    Neelakantham, Srikanth
    Dumitras, Swati
    Legangneux, Eric
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 175 - 195
12345